TRCT
SVA

Tower Research Capital (TRC)’s Sinovac Biotech, Ltd SVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
424
– – ﹤0.01% 5719
2025
Q4 		$0 Hold
424
– – ﹤0.01% 5757
2025
Q3 		$0 Hold
424
– – ﹤0.01% 5767
2025
Q2 		$0 Buy
+424
New – ﹤0.01% 5702
2024
Q3 		– Sell
-424
Closed – – 6172
2024
Q2 		$0 Hold
424
– – ﹤0.01% 6212
2024
Q1 		$0 Buy
+424
New – ﹤0.01% 6375
2023
Q4 		– Sell
-424
Closed – – 6439
2023
Q3 		$0 Hold
424
– – ﹤0.01% 6527
2023
Q2 		$0 Buy
+424
New – ﹤0.01% 6688
2023
Q1 		– Sell
-424
Closed – – 6822
2022
Q4 		$0 Hold
424
– – ﹤0.01% 6980
2022
Q3 		$0 Hold
424
– – ﹤0.01% 7020
2022
Q2 		$0 Hold
424
– – ﹤0.01% 7123
2022
Q1 		$0 Hold
424
– – ﹤0.01% 7229
2021
Q4 		$0 Hold
424
– – ﹤0.01% 7138
2021
Q3 		$0 Hold
424
– – ﹤0.01% 6695
2021
Q2 		$0 Hold
424
– – ﹤0.01% 6372
2021
Q1 		$0 Hold
424
– – ﹤0.01% 6094
2020
Q4 		$0 Hold
424
– – ﹤0.01% 5674
2020
Q3 		$0 Buy
+424
New – ﹤0.01% 5385
2020
Q1 		– Sell
-424
Closed -$3K – 4499
2019
Q4 		$3K Buy
+424
New +$3K ﹤0.01% 3008
2019
Q3 		– Sell
-424
Closed -$3K – 4895
2019
Q2 		$3K Hold
424
– – ﹤0.01% 3220
2019
Q1 		$3K Buy
424
+89
+27% +$585 ﹤0.01% 3366
2018
Q4 		$2K Buy
335
+75
+29% +$548 ﹤0.01% 3529
2018
Q3 		$2K Buy
+260
New +$1.88K ﹤0.01% 3545
2018
Q2 		– Sell
-20
Closed – – 4489
2018
Q1 		$0 Buy
+20
New +$165 ﹤0.01% 4343
2017
Q4 		– Sell
-68
Closed – – 4526
2017
Q3 		$0 Sell
68
-819
-92% -$5.59K ﹤0.01% 4507
2017
Q2 		$6K Buy
+887
New +$4.86K ﹤0.01% 1959
2017
Q1 		– Sell
-1,607
Closed -$10K – 4676
2016
Q4 		$10K Sell
1,607
-641
-29% -$3.85K ﹤0.01% 2701
2016
Q3 		$14K Sell
2,248
-128
-5% -$753 ﹤0.01% 1862
2016
Q2 		$14K Sell
2,376
-583
-20% -$3.57K ﹤0.01% 2570
2016
Q1 		$19K Buy
2,959
+786
+36% +$4.72K ﹤0.01% 1415
2015
Q4 		$12K Buy
2,173
+2,094
+2,651% +$11.3K ﹤0.01% 1973
2015
Q3 		$0 Buy
+79
New +$418 ﹤0.01% 5723
2015
Q2 		– Sell
-2,589
Closed -$12K – 5787
2015
Q1 		$12K Buy
2,589
+1,658
+178% +$8.17K ﹤0.01% 2693
2014
Q4 		$5K Sell
931
-7,840
-89% -$40K ﹤0.01% 2825
2014
Q3 		$42K Buy
8,771
+5,323
+154% +$28.6K ﹤0.01% 1694
2014
Q2 		$19K Sell
3,448
-42
-1% -$255 ﹤0.01% 1895
2014
Q1 		$25K Buy
3,490
+2,894
+486% +$19.2K ﹤0.01% 1707
2013
Q4 		$4K Buy
596
+454
+320% +$2.73K ﹤0.01% 3800
2013
Q3 		$1K Sell
142
-20,083
-99% -$96K ﹤0.01% 4508
2013
Q2 		$79K Buy
+20,225
New +$75.3K 0.01% 634

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Tower Research Capital (TRC)'s SVA Position: Q1 2026 in Review

Tower Research Capital (TRC) held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 424 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5719.

Tower Research Capital (TRC) first reported a position in SVA in Q2 2013 and has held it in 40 quarters since. The position peaked at $79K in Q2 2013. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Tower Research Capital (TRC) held 424 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
  • Tower Research Capital (TRC) left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5719 holding.
  • Tower Research Capital (TRC) first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 40 quarters since.
  • Tower Research Capital (TRC)'s Sinovac Biotech, Ltd position peaked at $79K in Q2 2013.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.